May 23 (Reuters) - Tango Therapeutics said on Thursday it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.54 USD | +1.71% | +25.36% | -3.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.64% | 1.02B | |
+34.01% | 51.07B | |
+33.84% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- TNGX Stock
- News Tango Therapeutics, Inc.
- Tango Therapeutics to stop development of cancer therapy